您好,欢迎来到科研在线!科研采购 · 选型 · 实验方法
首页产品库品牌馆产品类别品牌新闻会议会展产品试用求职招聘资讯专题教程
PRO / Antibodies

Anti-Human PD-L1 (Envafolimab Biosimilar)

Anti-Human PD-L1 (Envafolimab Biosimilar)

英诺赛图(InnoCyto)的 Anti-Human PD-L1 (Envafolimab Biosimilar)(克隆 Envafolimab) 为人源 IgG1 抗体,靶向 PD-L1(别名 PDL1 CD274 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。

生物试剂 供应商 上海英诺赛图 ↗ 型号 502501 更新 2026-11-12
参考价格区间
¥1,695
含税参考价,实际以配置与渠道报价为准
本条目供应商 上海英诺赛图原厂 1865个条目 进入企业主页

01产品图片

02产品简介

英诺赛图(InnoCyto)的 Anti-Human PD-L1 (Envafolimab Biosimilar)(克隆 Envafolimab) 为人源 IgG1 抗体,靶向 PD-L1(别名 PDL1 CD274 等),适用于流式细胞术。提供 1 mg、5 mg、20 mg 规格,目录价 ¥1,695 起,仅供科研使用(RUO)。

03产品介绍

规格与货号

502501 | 1 mg | ¥1,695

502502 | 5 mg | ¥4,407

502503 | 20 mg | ¥13,560

Product Details

Product Description|Anti-Human PD-L1 (Envafolimab Biosimilar)

Regulatory Status|RUO

Species specificity|Human

Storage Conditions|4ºC

Maximal Shelf Life|12 months

See All Formats|Clone Envafolimab

Background Information

Envafolimab, also known as KN035, is a novel recombinant single-domain antibody–Fc fusion protein engineered to specifically target programmed death-ligand 1 (PD-L1). Structurally, Envafolimab is distinct from conventional monoclonal antibodies because it consists of only the heavy-chain variable domain (VH) derived from camelid antibody fragments, fused directly to the Fc (fragment crystallizable) region of human immunoglobulin G1 (IgG1). This configuration results in a smaller, single-chain architecture with a molecular weight of approximately 80 kilodaltons (kDa), roughly half that of a full-length IgG molecule. The molecule is produced in mammalian expression systems to maintain proper folding, disulfide bond formation, and glycosylation within the Fc portion.

The single-domain variable region of Envafolimab provides specificity for PD-L1 through high-affinity interactions dominated by hydrogen bonding and hydrophobic contacts. Upon binding, Envafolimab effectively blocks PD-L1 from engaging its receptors, programmed death-1 (PD-1) and B7.1 (CD80), on activated T lymphocytes and antigen-presenting cells. This blockade disrupts inhibitory signaling pathways that would otherwise reduce T-cell proliferation and cytokine secretion. Functionally, this mechanism restores or enhances immune cell activation in experimental systems, making Envafolimab a valuable tool for the study of immune checkpoint regulation and ligand–receptor signaling.

The Fc region of Envafolimab contributes structural stability, mediates dimerization, and extends circulatory half-life through interactions with neonatal Fc receptors (FcRn), which protect the molecule from lysosomal degradation. Because the Fc segment is derived from IgG1, it retains potential for limited Fc receptor binding, though it is not primarily designed for effector function. The compact and stable single-domain architecture grants Envafolimab notable advantages in solubility, tissue penetration, and molecular stability. Overall, Envafolimab exemplifies advanced protein engineering that fuses minimal antigen-binding domains with antibody Fc functionality to create a small, high-affinity immune checkpoint inhibitor optimized for mechanistic and biochemical research applications.

Data Sheets

Cat # Size Price Quantity 5025011 mg Add to Cart5025025 mg Add to Cart50250320 mg Add to Cart

04完整参数表

参数由厂商资料整理,采购前请以最终报价单与技术协议为准。

包装规格1 mg
CloneEnvafolimab
ApplicationFlow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionAnti-Human PD-L1 (Envafolimab Biosimilar)
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman PD-L1
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Storage Conditions4ºC
SynonymsCD274, B7-H1
RRIDAB_3739301
Target NamePD-L1, PDL1 CD274, B7-H1
Antibody TypeRecombinant
目录价¥1,695

05荣誉与资质

该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。

  • 营业执照未上传
  • 品牌授权未上传
  • 产品检测报告未上传
会员身份
收费会员
经营身份
原厂
成立年份
2020 年
所在地
上海
收录条目
1865 个
平台核验
平台代管
向品牌方索取资质文件

06品牌与供应商

上海英诺赛图 原厂
InnoCyto

以可信赖的细胞研究试剂,助力科研突破

进入企业主页
1865 本目录条目
产地 / 总部上海市浦东新区
成立年份2020 年
本目录主营生化试剂 / 蛋白与抗体

InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。

售后与服务

品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。

引用此条目 产品目录 · 更新于 2026-11-12
科研在线(TeleVM). Anti-Human PD-L1 (Envafolimab Biosimilar)(502501)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-pd-l1-envafolimab-biosimilar.html.
TeleVM. (2026, November 12). Anti-Human PD-L1 (Envafolimab Biosimilar)(502501). 产品目录. https://www.suprotek.cn/products/item/anti-human-pd-l1-envafolimab-biosimilar.html
@misc{biocsp_item_anti_human_pd_l1_envafolimab_biosimilar,
  title        = {Anti-Human PD-L1 (Envafolimab Biosimilar)(502501)},
  author       = {{科研在线}},
  year         = {2026},
  howpublished = {产品目录},
  note         = {更新于 2026-11-12,产品目录},
  url          = {https://www.suprotek.cn/products/item/anti-human-pd-l1-envafolimab-biosimilar.html}
}

GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。

许可:CC BY-NC 4.0 · 转载注明来源
获取正式报价

Anti-Human PD-L1 (Envafolimab Biosimilar)

提交后由平台转给品牌方,通常 1 个工作日内联系。不需要注册。